Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07206225

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.

This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them.

The study has three parts:

* Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments.

All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin.

For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-Muscle Invasive Bladder Cancer Carcinoma Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non-Muscle Invasive Bladder Neoplasms Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Gustave Roussy, Villejuif, VAL DE Marne, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older (or the minimum age of consent per local regulations)
  • Histological diagnosis of high-risk, non-muscle invasive urothelial carcinoma of the bladder defined according to the WHO grading system as carcinoma in situ (CIS), with or without concurrent T1/Ta papillary disease. Note: High-grade T1/Ta papillary disease, in the absence of CIS, may be eligible for certain cohorts in Part 2 and 3
  • BCG unresponsive and BCG-exposed cohorts should have persistent or recurrent disease after receiving at least 5 out of 6 doses of the BCG induction therapy.
  • Have refused or are ineligible or not appropriate for radical cystectomy
  • Tissue Requirement: Available tumor tissue within the last 6 months. On-treatment tumor biopsy is optional, unless mandated based on emerging data, or participating in the Biomarker Cohort, or for disease assessment
  • ECOG PS 0 or 1

Exclusion criteria

  • Concomitant anti-cancer therapy for Non-Muscle Invasive Bladder Cancer (NMIBC); and prior radiation therapy to the bladder are not allowed
  • Renal or hepatic impairment; and hematologic abnormalities as defined in the protocol
  • Participants with active, uncontrolled infection as specified in the protocol

Treatment and study plan

PF-08052667

Drug

PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash

Other names: SGN-B6N

Sasanlimab

Drug

Sasanlimab will be administered as subcutaneous (SC) injection

Other names: PF-06801591

BCG

Drug

BCG will be administered intravesical (IVe) instillation

PF-02921367

Drug

PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation

Other names: DDM

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants only

    Time frame: Day of first dose (Day 1) Up to 21 days

    Any AE occurring during the DLT observation period that is attributed to PF-08052667 and not to the underlying disease or other causes is considered a DLT. DLT rate estimated based on data from DLT-evaluable participants during the DLT evaluation period.

  2. Number of participants with adverse events (AEs) in Part 1 and Part 2 participants only

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

    AEs as characterized by type, frequency, severity (CTCAE v5.0), seriousness, and relatedness to study drug(s).

  3. Number of participants with laboratory abnormalities in Part 1 and Part 2 participants only

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

    Laboratory abnormalities as characterized by type, frequency, severity

  4. Recurrence-free survival (RFS) in Part 3 participants only

    Time frame: Through end of study and up to approximately 2 years

    RFS is defined as the time from the first dose until recurrence of high-grade disease, or death due to any cause, whichever occurs first

  5. Event-free survival (EFS) in Part 3 participants only

    Time frame: Through end of study and up to approximately 2 years

    EFS is defined as the time from the first dose until the first occurrence of an EFS event including progressive disease, recurrence of high-grade disease, or death due to any cause, whichever occurs first

Secondary outcomes

  1. PK: Maximum Observed Serum Concentration (Cmax)

    Time frame: From the first day through 30-37 days after the last study treatment

    Cmax of PF-08052667as a monotherapy (Part 1) and in combination with BCG and/or sasanlimab (Part 2 and Part 3)

  2. PK: Time to Reach Maximum Observed Serum Concentration (Tmax)

    Time frame: From the first day through 30-37 days after the last study treatment

    Tmax of PF-08052667as a monotherapy (Part 1) and in combination with BCG and/or sasanlimab (Part 2 and Part 3)

  3. PK: Minimum observed serum concentration (Ctrough)

    Time frame: From the first day through 30-37 days after the last study treatment

    Ctrough of PF-08052667as a monotherapy (Part 1) and in combination with BCG and/or sasanlimab (Part 2 and Part 3)

  4. PK: Area under the concentration-time curve (AUC) from time zero to last (AUC from time 0 to AUClast)

    Time frame: From the first day through 30-37 days after the last study treatment

    AUClast of PF-08052667as a monotherapy (Part 1) and in combination with BCG and/or sasanlimab (Part 2 and Part 3)

  5. PK: Half-life (t1/2)

    Time frame: From the first day through 30-37 days after the last study treatment

  6. Incidence of Anti-Drug Antibody (ADA): Immunogenicity of PF-08052667 as a single agent (Part 1) and in combination with BCG and/or sasanlimab (Part 2 and Part 3)

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

    Incidence and titers of ADA and neutralizing antibody against PF-08052667

  7. Duration of Complete Response (CR) in Part 1 and Part 2 participants only

    Time frame: Through end of study and up to approximately 2 years

    Duration of CR is the time from first documentation of CR until the first occurrence of an Event-free survival (EFS) event

  8. Complete Response Rate (CRR) in Part 1 and Part 2 participants only

    Time frame: Through end of study and up to approximately 2 years

    CR rate is defined as the proportion of subjects achieving CR

  9. Overall survival (OS) in Part 3 participants only

    Time frame: Through end of study approximately 5 years from last participant enrollment

    Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause

  10. Cystectomy-free survival in all Parts

    Time frame: Through end of study and up to approximately 2 years

    Cystectomy-free survival is defined as the time from the first dose until cystectomy or death due to any cause, whichever occurs first

  11. Event-free survival (EFS) in Part 1 and Part 2 participants only

    Time frame: Through end of study and up to approximately 2 years

    EFS is defined as the time from the first dose until the first occurrence of an EFS event including progressive disease, recurrence of high-grade disease, or death due to any cause, whichever occurs first

  12. Recurrence-free survival (RFS) in Part 1 and Part 2 participants only

    Time frame: Through end of study and up to approximately 2 years

    RFS is defined as the time from the first dose until recurrence of high-grade disease, or death due to any cause, whichever occurs first

  13. Rate of cystectomy in all parts

    Time frame: Through end of study and up to approximately 2 years

    Rate of cystectomy is defined as the proportion of participants who had a cystectomy while on study

  14. Number of participants with adverse events (AEs) in Part 3 participants only

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

    AEs as characterized by type, frequency, severity (CTCAE v5.0), seriousness, and relatedness to study drug(s)

  15. Number of participants with laboratory abnormalities in Part3 participants only

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

    Laboratory abnormalities as characterized by type, frequency, severity

Study contacts

Contact information is provided by the study sponsor or research team.

Pfizer CT.gov Call Center

CONTACT

[email protected]

1-800-718-1021

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER

Important dates

Study start
2025
Primary completion
2030
Study completion
2033
First posted
Oct 3, 2025
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.